Penserra Capital Management LLC Acquires Shares of 44,180 Harrow, Inc. (NASDAQ:HROW)

Penserra Capital Management LLC bought a new stake in shares of Harrow, Inc. (NASDAQ:HROW) in the third quarter, Holdings Channel reports. The firm bought 44,180 shares of the company’s stock, valued at approximately $1,986,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Harrow by 1.2% during the first quarter. Vanguard Group Inc. now owns 1,829,805 shares of the company’s stock worth $24,208,000 after acquiring an additional 21,253 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new stake in shares of Harrow during the 3rd quarter valued at about $1,267,000. SG Americas Securities LLC bought a new stake in shares of Harrow in the 3rd quarter valued at approximately $534,000. Semanteon Capital Management LP bought a new stake in shares of Harrow in the 3rd quarter valued at approximately $686,000. Finally, Private Capital Management LLC increased its holdings in Harrow by 7.8% in the first quarter. Private Capital Management LLC now owns 3,012,393 shares of the company’s stock worth $39,854,000 after buying an additional 217,896 shares during the last quarter. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Harrow Stock Down 2.0 %

Shares of Harrow stock opened at $42.06 on Tuesday. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The stock has a 50 day moving average price of $47.88 and a two-hundred day moving average price of $33.67. The stock has a market capitalization of $1.50 billion, a P/E ratio of -45.64 and a beta of 0.76. Harrow, Inc. has a 12-month low of $8.72 and a 12-month high of $59.23.

Wall Street Analysts Forecast Growth

HROW has been the subject of a number of analyst reports. B. Riley reiterated a “buy” rating and issued a $50.00 target price on shares of Harrow in a research note on Thursday, August 29th. Craig Hallum lifted their price objective on shares of Harrow from $45.00 to $65.00 and gave the company a “buy” rating in a research note on Friday, October 4th. Finally, Lake Street Capital increased their target price on shares of Harrow from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, October 4th.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.